Aliskiren: the first renin inhibitor for clinical treatment

@article{Jensen2008AliskirenTF,
  title={Aliskiren: the first renin inhibitor for clinical treatment},
  author={Chris Jensen and Peter Dr Herold and Hans Rudolf Brunner},
  journal={Nature Reviews Drug Discovery},
  year={2008},
  volume={7},
  pages={399-410}
}
The first evidence of the existence of renin was presented over 100 years ago. However, the importance of renin and the renin–angiotensin system in the pathogenesis of cardiovascular disease was only fully realized in the 1970s. It was another 20 years before the first inhibitors of renin were available for clinical research. Here, we describe the discovery and development of aliskiren, an orally active renin inhibitor, which became the first drug in its class to receive regulatory approval. In… Expand
Aliskiren and dual therapy in type 2 diabetes mellitus.
The discovery 110 years ago that crude kidney extract elicited a pressor reaction provided the first evidence of the existence of the renin–angiotensin–aldosterone system, a major vasoactive system,1Expand
Renin inhibitor in hypertension treatment: from pharmacological point of view
TLDR
Aliskiren becomes the first renin inhibitor with indications for the treatment of hypertension in Indonesia, a compounds with improved oral bioavailability, specificity and efficacy, with a focus on aliskiren. Expand
Antihypertensives: Renin Inhibitors
Renin has been recognized as an attractive target for antihypertensive drugs since the 1950s. Intensive efforts in the 1980s focused on peptidomimetic hydroxy transition-state isosteres led to manyExpand
Recent progress on the discovery of non-peptidic direct renin inhibitors for the clinical management of hypertension
  • F. Yokokawa
  • Medicine
  • Expert opinion on drug discovery
  • 2013
TLDR
The present review summarizes the recent scientific accounts describing the design of new non-peptidic DRIs published between 2009 and 2012 and presents a number of chemical structures in addition to preclinical ADMET obtained from public scientific literatures and patent filings. Expand
Aliskiren, the first direct renin inhibitor for treatment of hypertension: the path of its development.
TLDR
Aliskiren is the first DRI for the treatment of hypertension, designed through a combination of molecular modeling techniques and crystal structure elucidation, and effectively reduces the blood pressure as a mono therapy as well in combination therapy. Expand
Renin Inhibitors and Cardiovascular and Renal Protection: An Endless Quest?
TLDR
Aliskiren's pharmacological profile in patients with hypertension, diabetic nephropathy or heart failure, in addition to experimental evidence, suggests that aliskiren may be of value for the management of cardiovascular and renal diseases. Expand
Recent advances in the discovery of non-peptidic direct renin inhibitors as antihypertensives: new patent applications in years 2000 – 2008
Background: The renin-angiotensin-aldosterone system (RAAS) is essential for the regulation of blood pressure and may play a critical role in the pathogenesis of cardiovascular diseases. A strongExpand
Chapter 5 Case History on Tekturna®/Rasilez® (Aliskiren), a Highly Efficacious Direct Oral Renin Inhibitor as a New Therapy for Hypertension
TLDR
Aliskiren has demonstrated orally active anti-hypertensive efficacy and end-organ protection and is safe and well-tolerated in pre-clinical and clinical trials. Expand
Is there a future for direct renin inhibitors?
TLDR
Aliskiren – alone or in combination – might offer a novel therapeutic intervention to improve suppression of the RAAS, with potential to translate to improved CVD and CKD outcomes. Expand
Antihypertensive and renoprotective mechanisms of Renin inhibition in diabetic rats.
TLDR
Blockade of the RAS with angiotensin converting enzyme (ACE) inhibitors or angiotsin type-1 receptor blockers (ARBs) retards but does not eliminate the progression of diabetic nephropathy to ESRD in prospective, randomized, controlled clinical trials. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 105 REFERENCES
Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness.
TLDR
Until the possibility is eliminated of inducing increases in blood pressure with aliskiren in patients with highly reactive renin levels, it seems safe and simple to stick to the less expensive, equally effective and widely available generic CEI drugs for treating the renin factor in hypertension. Expand
Structure-based design of aliskiren, a novel orally effective renin inhibitor.
TLDR
Aliskiren is the first in a novel class of renin inhibitors with the potential for treatment of hypertension and related cardiovascular diseases and employs a combination of molecular modelling and crystallographic structure analysis to design renin inhibitor lacking the extended peptide-like backbone of earlier inhibitors. Expand
Discovery of remikiren as the first orally active renin inhibitor.
TLDR
Clinical results seem to confirm the preclinical findings and show that remikiren is indeed a potent orally active renin inhibitor inducing a long lasting blood pressure decrease. Expand
Direct renin inhibition with aliskiren in hypertension and target organ damage.
  • D. Müller, F. Luft
  • Medicine
  • Clinical journal of the American Society of Nephrology : CJASN
  • 2006
TLDR
Aliskiren, a once-daily, orally effective, small-molecule renin inhibitor, is now available to address angiotensin production directly at its rate-limiting step, and offers a novel circumvention. Expand
Blood Pressure Lowering in Essential Hypertension With an Oral Renin Inhibitor, Aliskiren
TLDR
It is demonstrated that aliskiren, through inhibition of renin, is an effective and safe orally active BP-lowering agent and well tolerated at all doses studied. Expand
Angiotensin II Suppression in Humans by the Orally Active Renin Inhibitor Aliskiren (SPP100): Comparison With Enalapril
TLDR
Aliskiren has the potential to become the first orally active renin inhibitor that provides a true alternative to ACE-inhibitors and Ang II receptor antagonists in therapy for hypertension and other cardiovascular and renal diseases. Expand
Long-term treatment of hypertension in man by an orally active angiotensin-converting enzyme inhibitor.
1. Captopril or SQ 14 225, administered orally twice a day, reduced the blood pressure of hypertensive patients whatever their clinical diagnosis and even when their plasma renin activity wasExpand
Persistent formation of angiotensin II despite treatment with maximally recommended doses of angiotensin converting enzyme inhibitors in patients with chronic heart failure
TLDR
Several large, randomised, placebo-controlled trials have shown that angiotensin converting enzyme (ACE) inhibition enhances life expectancy and alleviates symptoms in patients with CHF and with acute myocardial infarction and left ventricular (LV) systolic dysfunction. Expand
Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects
TLDR
The oral renin inhibitor aliskiren demonstrated similar pharmacokinetic and pharmacodynamic properties in Japanese and Caucasian subjects. Expand
Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide
TLDR
Aliskiren monotherapy demonstrated significant BP lowering, and its effect was considerably greater when combined with HCTZ, and Renin inhibition with aliskiren neutralized the compensatory rise in PRA induced by HCTz. Expand
...
1
2
3
4
5
...